

Tae-Wook Chun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/73622/publications.pdf>

Version: 2024-02-01

118
papers

18,824
citations

19657

61
h-index

20961

115
g-index

122
all docs

122
docs citations

122
times ranked

12303
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. <i>Nature</i> , 1997, 387, 183-188.	27.8	1,921
2	Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 13193-13197.	7.1	1,786
3	Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. <i>Journal of Experimental Medicine</i> , 2008, 205, 1797-1805.	8.5	782
4	Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 8869-8873.	7.1	764
5	In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency. <i>Nature Medicine</i> , 1995, 1, 1284-1290.	30.7	709
6	Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. <i>Journal of Experimental Medicine</i> , 2008, 205, 2763-2779.	8.5	681
7	Absence of Detectable HIV-1 Viremia after Treatment Cessation in an Infant. <i>New England Journal of Medicine</i> , 2013, 369, 1828-1835.	27.0	520
8	Persistence of HIV in Gut-Associated Lymphoid Tissue despite Long-Term Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2008, 197, 714-720.	4.0	489
9	Towards an HIV cure: a global scientific strategy. <i>Nature Reviews Immunology</i> , 2012, 12, 607-614.	22.7	485
10	Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. <i>Nature Medicine</i> , 2000, 6, 757-761.	30.7	404
11	Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. <i>Nature Medicine</i> , 1999, 5, 651-655.	30.7	400
12	Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. <i>New England Journal of Medicine</i> , 2016, 375, 2037-2050.	27.0	391
13	Re-emergence of HIV after stopping therapy. <i>Nature</i> , 1999, 401, 874-875.	27.8	390
14	Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. <i>Science Translational Medicine</i> , 2015, 7, 319ra206.	12.4	390
15	Induction of HIV-1 Replication in Latently Infected CD4+ T Cells Using a Combination of Cytokines. <i>Journal of Experimental Medicine</i> , 1998, 188, 83-91.	8.5	344
16	Latent reservoirs of HIV: Obstacles to the eradication of virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 10958-10961.	7.1	317
17	Pathogenic Mechanisms of HIV Disease. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2011, 6, 223-248.	22.4	312
18	HIV Persistence and the Prospect of Long-Term Drug-Free Remissions for HIV-Infected Individuals. <i>Science</i> , 2010, 329, 174-180.	12.6	274

#	ARTICLE	IF	CITATIONS
19	HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. <i>Journal of Clinical Investigation</i> , 2005, 115, 3250-3255.	8.2	246
20	Distinct viral reservoirs in individuals with spontaneous control of HIV-1. <i>Nature</i> , 2020, 585, 261-267.	27.8	245
21	Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin Patient. <i>PLoS Pathogens</i> , 2013, 9, e1003347.	4.7	244
22	Early antibody therapy can induce long-lasting immunity to SHIV. <i>Nature</i> , 2017, 543, 559-563.	27.8	244
23	B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. <i>Blood</i> , 2010, 116, 5571-5579.	1.4	234
24	Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. <i>Aids</i> , 2010, 24, 2803-2808.	2.2	233
25	Decreased Survival of B Cells of HIV-viremic Patients Mediated by Altered Expression of Receptors of the TNF Superfamily. <i>Journal of Experimental Medicine</i> , 2004, 200, 587-600.	8.5	211
26	Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy. <i>Journal of Clinical Investigation</i> , 2019, 129, 988-998.	8.2	209
27	HIV reservoirs as obstacles and opportunities for an HIV cure. <i>Nature Immunology</i> , 2015, 16, 584-589.	14.5	200
28	Both Memory and CD45RA ⁺ /CD62L ⁺ Naive CD4 ⁺ T Cells Are Infected in Human Immunodeficiency Virus Type 1-Infected Individuals. <i>Journal of Virology</i> , 1999, 73, 6430-6435.	3.4	200
29	Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: Correlation with increased IL-7. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 2262-2267.	7.1	180
30	Decay of the HIV Reservoir in Patients Receiving Antiretroviral Therapy for Extended Periods: Implications for Eradication of Virus. <i>Journal of Infectious Diseases</i> , 2007, 195, 1762-1764.	4.0	180
31	B Cells of HIV-1-Infected Patients Bind Virions through Cd21 Complement Interactions and Transmit Infectious Virus to Activated T Cells. <i>Journal of Experimental Medicine</i> , 2000, 192, 637-646.	8.5	178
32	Gene expression and viral production in latently infected, resting CD4 ⁺ T cells in viremic versus aviremic HIV-infected individuals. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 1908-1913.	7.1	174
33	Innate Immunity in Human Immunodeficiency Virus Infection: Effect of Viremia on Natural Killer Cell Function. <i>Journal of Infectious Diseases</i> , 2003, 187, 1038-1045.	4.0	151
34	HIV reservoirs. <i>Aids</i> , 2012, 26, 1261-1268.	2.2	151
35	Relationship Between Residual Plasma Viremia and the Size of HIV Proviral DNA Reservoirs in Infected Individuals Receiving Effective Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2011, 204, 135-138.	4.0	145
36	Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 11698-11703.	7.1	130

#	ARTICLE	IF	CITATIONS
37	Abnormal B cell memory subsets dominate HIV-specific responses in infected individuals. <i>Journal of Clinical Investigation</i> , 2014, 124, 3252-3262.	8.2	130
38	The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. <i>Journal of Infectious Diseases</i> , 2018, 218, 1954-1963.	4.0	130
39	Normalization of B Cell Counts and Subpopulations after Antiretroviral Therapy in Chronic HIV Disease. <i>Journal of Infectious Diseases</i> , 2008, 197, 572-579.	4.0	128
40	Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy. <i>Aids</i> , 2011, 25, 741-749.	2.2	126
41	HIV Type 1 (HIV-1) Proviral Reservoirs Decay Continuously Under Sustained Virologic Control in HIV-1â€“Infected Children Who Received Early Treatment. <i>Journal of Infectious Diseases</i> , 2014, 210, 1529-1538.	4.0	123
42	Relationship between the Size of the Human Immunodeficiency Virus Type 1 (HIVâ€“1) Reservoir in Peripheral Blood CD4+T Cells and CD4+:CD8+T Cell Ratios in Aviremic HIVâ€“1â€“Infected Individuals Receiving Longâ€“Term Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2002, 185, 1672-1676.	4.0	122
43	Attenuation of HIV-associated human B cell exhaustion by siRNA downregulation of inhibitory receptors. <i>Journal of Clinical Investigation</i> , 2011, 121, 2614-2624.	8.2	121
44	Glycosylation, Hypogammaglobulinemia, and Resistance to Viral Infections. <i>New England Journal of Medicine</i> , 2014, 370, 1615-1625.	27.0	117
45	Anti-apoptotic Protein BIRC5 Maintains Survival of HIV-1-Infected CD4+ T Cells. <i>Immunity</i> , 2018, 48, 1183-1194.e5.	14.3	109
46	A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	105
47	Deleterious Effect of HIV-1 Plasma Viremia on B Cell Costimulatory Function. <i>Journal of Immunology</i> , 2003, 170, 5965-5972.	0.8	95
48	Pilot Study of the Effects of Intermittent Interleukinâ€“2 on Human Immunodeficiency Virus (HIV)â€“Specific Immune Responses in Patients Treated during Recently Acquired HIV Infection. <i>Journal of Infectious Diseases</i> , 2002, 185, 61-8.	4.0	86
49	Comprehensive analysis of unique cases with extraordinary control over HIV replication. <i>Blood</i> , 2012, 119, 4645-4655.	1.4	86
50	Effect of Histone Deacetylase Inhibitors on HIV Production in Latently Infected, Resting CD4+ T Cells From Infected Individuals Receiving Effective Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2012, 206, 765-769.	4.0	83
51	Paucity of HIV DNA Methylation in Latently Infected, Resting CD4 ⁺ T Cells from Infected Individuals Receiving Antiretroviral Therapy. <i>Journal of Virology</i> , 2012, 86, 5390-5392.	3.4	79
52	Early Initiation of Combination Antiretroviral Therapy in HIV-1-Infected Newborns Can Achieve Sustained Virologic Suppression With Low Frequency of CD4+ T Cells Carrying HIV in Peripheral Blood. <i>Clinical Infectious Diseases</i> , 2014, 59, 1012-1019.	5.8	77
53	Prolonged viral suppression with anti-HIV-1 antibody therapy. <i>Nature</i> , 2022, 606, 368-374.	27.8	75
54	Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: Implications for the development of therapeutic strategies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 253-258.	7.1	74

#	ARTICLE	IF	CITATIONS
55	Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals. <i>PLoS Pathogens</i> , 2018, 14, e1006792.	4.7	74
56	Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes. <i>Nature Medicine</i> , 2001, 7, 1225-1231.	30.7	73
57	Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 6057-6062.	7.1	73
58	Two overrepresented B cell populations in HIV-infected individuals undergo apoptosis by different mechanisms. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 19436-19441.	7.1	73
59	In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication. <i>PLoS Pathogens</i> , 2017, 13, e1006575.	4.7	73
60	Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 13151-13156.	7.1	72
61	Biochemical and Biological Characterization of a Dodecameric CD4-Ig Fusion Protein. <i>Journal of Biological Chemistry</i> , 2002, 277, 11456-11464.	3.4	71
62	Impact of HIV on Cell Survival and Antiviral Activity of Plasmacytoid Dendritic Cells. <i>PLoS ONE</i> , 2007, 2, e458.	2.5	68
63	Overexpression of T-bet in HIV infection is associated with accumulation of B cells outside germinal centers and poor affinity maturation. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	65
64	Combination anti-HIV antibodies provide sustained virological suppression. <i>Nature</i> , 2022, 606, 375-381.	27.8	65
65	CD40-Mediated Induction of CD4 and CXCR4 on B Lymphocytes Correlates with Restricted Susceptibility to Human Immunodeficiency Virus Type 1 Infection: Potential Role of B Lymphocytes as a Viral Reservoir. <i>Journal of Virology</i> , 1999, 73, 7972-7980.	3.4	61
66	Characterization of Plasmablasts in the Blood of HIV-Infected Viremic Individuals: Evidence for Nonspecific Immune Activation. <i>Journal of Virology</i> , 2013, 87, 5800-5811.	3.4	57
67	Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers. <i>Journal of Infectious Diseases</i> , 2013, 208, 1443-1447.	4.0	56
68	Relationship between the frequency of HIV-specific CD8+ T cells and the level of CD38+CD8+ T cells in untreated HIV-infected individuals. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 2464-2469.	7.1	55
69	Longitudinal clonal dynamics of HIV-1 latent reservoirs measured by combination quadruplex polymerase chain reaction and sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	52
70	Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study. <i>PLoS Medicine</i> , 2017, 14, e1002461.	8.4	50
71	High frequencies of resting CD4 ⁺ T cells containing integrated viral DNA are found in rhesus macaques during acute lentivirus infections. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 8015-8020.	7.1	45
72	Rational Design of Drugs That Induce Human Immunodeficiency Virus Replication. <i>Journal of Virology</i> , 2003, 77, 10227-10236.	3.4	44

#	ARTICLE	IF	CITATIONS
73	Maintenance of HIV-Specific Memory B-Cell Responses in Elite Controllers Despite Low Viral Burdens. <i>Journal of Infectious Diseases</i> , 2016, 214, 390-398.	4.0	43
74	Genetic Characterization of Rebounding Human Immunodeficiency Virus Type 1 in Plasma during Multiple Interruptions of Highly Active Antiretroviral Therapy. <i>Journal of Virology</i> , 2003, 77, 3229-3237.	3.4	42
75	Maturational characteristics of HIV-specific antibodies in viremic individuals. <i>JCI Insight</i> , 2016, 1, .	5.0	42
76	Conflicting evidence for HIV enrichment in CD32+ CD4 T cells. <i>Nature</i> , 2018, 561, E9-E16.	27.8	40
77	An open-label phase 1 clinical trial of the anti- CD4^{v2} CD7 monoclonal antibody vedolizumab in HIV-infected individuals. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	40
78	Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. <i>Journal of Experimental Medicine</i> , 2004, 200, 587-99.	8.5	38
79	Structural and Functional Characterization of CC Chemokine CCL14 ¹ . <i>Biochemistry</i> , 2007, 46, 10008-10015.	2.5	37
80	Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial. <i>PLoS Pathogens</i> , 2016, 12, e1005381.	4.7	37
81	Human Immunodeficiency Virus Type 1 Bound to B Cells: Relationship to Virus Replicating in CD4+ T Cells and Circulating in Plasma. <i>Journal of Virology</i> , 2002, 76, 8855-8863.	3.4	36
82	Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption. <i>New England Journal of Medicine</i> , 2019, 380, 1535-1545.	27.0	35
83	Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic window. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 10688-10698.	7.1	34
84	Role for CD21 in the Establishment of an Extracellular HIV Reservoir in Lymphoid Tissues. <i>Journal of Immunology</i> , 2007, 178, 6968-6974.	0.8	32
85	Humans with chronic granulomatous disease maintain humoral immunologic memory despite low frequencies of circulating memory B cells. <i>Blood</i> , 2012, 120, 4850-4858.	1.4	31
86	Quantification of plasma HIV RNA using chemically engineered peptide nucleic acids. <i>Nature Communications</i> , 2014, 5, 5079.	12.8	30
87	Accurate Prediction for Antibody Resistance of Clinical HIV-1 Isolates. <i>Scientific Reports</i> , 2019, 9, 14696.	3.3	30
88	Evaluation of the Pathogenesis of Decreasing CD4+T Cell Counts in Human Immunodeficiency Virus Type 1-Infected Patients Receiving Successfully Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2009, 199, 1648-1656.	4.0	27
89	IgG3 regulates tissue-like memory B cells in HIV-infected individuals. <i>Nature Immunology</i> , 2018, 19, 1001-1012.	14.5	27
90	Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals. <i>Aids</i> , 2011, 25, 295-302.	2.2	25

#	ARTICLE	IF	CITATIONS
91	Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir. JCI Insight, 2019, 4, .	5.0	25
92	Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy. Nature Medicine, 2021, 27, 1893-1898.	30.7	23
93	CXCR4/IgG-expressing plasma cells are associated with human gastrointestinal tissue inflammation. Journal of Allergy and Clinical Immunology, 2014, 133, 1676-1685.e5.	2.9	20
94	Kinetics of Plasma HIV Rebound in the Era of Modern Antiretroviral Therapy. Journal of Infectious Diseases, 2020, 222, 1655-1659.	4.0	19
95	Tracking replication-competent HIV reservoirs in infected individuals. Current Opinion in HIV and AIDS, 2013, 8, 111-116.	3.8	17
96	Early human B cell signatures of the primary antibody response to mRNA vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	17
97	HIV-1 targets L-selectin for adhesion and induces its shedding for viral release. Nature Communications, 2018, 9, 2825.	12.8	15
98	Durable Control of HIV Infection in the Absence of Antiretroviral Therapy. JAMA - Journal of the American Medical Association, 2019, 322, 27.	7.4	15
99	Short Communication: HIV Type 1 Accumulates in Influenza-Specific T Cells in Subjects Receiving Seasonal Vaccination in the Context of Effective Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2012, 28, 1687-1692.	1.1	13
100	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 514-518.	2.1	13
101	Bone Marrow Plasma Cells Are a Primary Source of Serum HIV-1-Specific Antibodies in Chronically Infected Individuals. Journal of Immunology, 2015, 194, 2561-2568.	0.8	13
102	Correlation Between TIGIT Expression on CD8+ T Cells and Higher Cytotoxic Capacity. Journal of Infectious Diseases, 2021, 224, 1599-1604.	4.0	13
103	Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral Therapy. Journal of Infectious Diseases, 2017, 216, 813-818.	4.0	12
104	Impact of Treatment Interruption on HIV Reservoirs and Lymphocyte Subsets in Individuals Who Initiated Antiretroviral Therapy During the Early Phase of Infection. Journal of Infectious Diseases, 2019, 220, 270-274.	4.0	11
105	Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria. Aids, 2021, 35, 2225-2227.	2.2	11
106	Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individuals. Journal of Clinical Investigation, 2019, 129, 4832-4837.	8.2	11
107	Continuous flow leukapheresis induces expression of stress genes in lymphocytes: impact on microarray analyses. Blood, 2003, 102, 3852-3853.	1.4	8
108	Viral Persistence in HIV Infection: Much Known, Much to Learn. Journal of Infectious Diseases, 2013, 208, 1356-1358.	4.0	6

#	ARTICLE	IF	CITATIONS
109	Delayed gastrointestinal-associated lymphoid tissue reconstitution in duodenum compared with rectum in HIV-infected patients initiating antiretroviral therapy. <i>Aids</i> , 2019, 33, 2289-2298.	2.2	6
110	Prolonged Posttreatment Virologic Control and Complete Seroreversion After Advanced Human Immunodeficiency Virus-1 Infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa613.	0.9	6
111	A Pilot Study of Raltegravir Plus Combination Antiretroviral Therapy in Early Human Immunodeficiency Virus Infection: Challenges and Lessons Learned. <i>BioResearch Open Access</i> , 2016, 5, 15-21.	2.6	5
112	HIV RNA Rebound in Seminal Plasma after Antiretroviral Treatment Interruption. <i>Journal of Virology</i> , 2020, 94, .	3.4	5
113	Authors' reply to correspondence by Le and Farrar. <i>Aids</i> , 2011, 25, 872-873.	2.2	2
114	Detection of HIV DNA and RNA Using PCR. <i>Current Protocols in Immunology</i> , 2001, 42, Unit 12.6.	3.6	1
115	Towards a cure for HIV: a long road ahead. <i>Retrovirology</i> , 2012, 9, .	2.0	1
116	395 The effect of elective C-section, preterm labor and chorioamnionitis on fetal lymphocyte activation and susceptibility to HIV infection. <i>American Journal of Obstetrics and Gynecology</i> , 2001, 185, S189.	1.3	0
117	Analytical treatment interruption in HIV-infected individuals: clinical perspectives. <i>Future Virology</i> , 2018, 13, 719-726.	1.8	0
118	Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. <i>Journal of Cell Biology</i> , 2008, 183, i9-i9.	5.2	0